Zantac makers handed court win in Delaware Jul. 11, 2025 7:08 AM ET GSK plc (GSK) Stock, PFE Stock By: Dulan Lokuwithana, SA News Editor 8 Comments Play (2min) memoriesarecaptured ...

Zantac owners Zantac hit the US market as a prescription drug in 1983 before transforming into an over-the-counter heartburn treatment in 1995. GSK and Warner Lambert developed it as part of a ...

Still, GSK has moved to settle many of the thousands of Zantac-related claims. Last fall, GSK agreed to pay up to $2.2 billion to resolve some 80,000 lawsuits, freeing it from litigating 93% of ...

These representations were materially false or misleading. In truth, GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market.

The Ohio AG’s office claims that GSK and its predecessor company hit an internal study in 1982 that showed Zantac can break down into compounds linked with causing cancer called NDMA. In 2019 ...

LOS ANGELES, April 2, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to GSK plc. ("GSK" or the "Company") (NYSE: GSK) have ...

The Ohio AG’s office claims that GSK and its predecessor company hit an internal study in 1982 that showed Zantac can break down into compounds linked with causing cancer called NDMA.